Project Grant R01HL182509
Award Date 9/1/25
Completion Date 6/30/30
Dollars Obligated $494K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Botswana
Similar Awards
- The National Heart Lung and Blood Institute awarded a $145,419 Project Grant titled "Implementation Determinants and Community-Based Prevention for Cardiometabolic Disease in Mozambique: A Pilot Study" under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports formative research to characterize determinants for effective implementation of integrated care for type 2 diabetes, hypertension, and HIV within ongoing health systems strengthening efforts in public...
- The Project Grant award of $692,846.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) will fund the "Better Heart Study" at the University of Pennsylvania. The study aims to utilize behavioral science strategies to increase hypertension diagnosis and treatment in India, where hypertension prevalence remains high and many individuals are undiagnosed or not receiving care. The project will test two scalable behavioral...
- This $223,438 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to assess the incidence of hypertension in antiretroviral therapy (ART)-naive people with HIV after initiating bictegravir versus dolutegravir-based ART, determine if weight gain is associated with incident hypertension, and evaluate HIV and non-HIV risk factors for incident hypertension. The award was granted to the University of Alabama at...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Mercer University totals $657,602 and aims to investigate the direct vascular effects of statins on regulating blood pressure, including potential mechanisms involving phosphodiesterase 1A inhibition and cyclic GMP signaling. The research will be conducted on resistance mesenteric arteries from normotensive and hypertensive animal models, with the goal of...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $763,858 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Inc.) to assess the impact of improving cardiovascular disease (CVD) care for adults with diagnosed diabetes across diverse global settings. The project, led by Dr. Jennifer Manne-Goehler and an interdisciplinary team, aims to develop the PREDICT-DM global...
- The National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), awarded a $688,525 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, San Diego (UCSD). The grant, titled "Blood Pressure Control Advancing Refugee Health Equity (BPCARE): An RCT of Adherence", aims to develop and test a behavioral intervention to improve antihypertensive medication adherence and blood pressure...
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $169,992 Project Grant to the University of Colorado-Denver on September 18, 2025. The grant will fund a 5-year mixed methods study to inform initial antihypertensive prescribing and develop a patient self-titration intervention. The study aims to understand barriers and facilitators to initiating antihypertensive combination therapy versus stepped...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program for Cardiovascular Diseases Research (CFDA 93.837), provides $123,104 to Emory University to conduct research on factors contributing to cardiovascular disease (CVD) comorbidities in persons living with HIV (PWH). The key objectives are to: 1) assess relationships between the metabolome, lipidome, HIV reservoir, and subclinical CVD, analyzing differences by sex; and 2) determine...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded a $549,125 project grant to Rutgers, The State University of New Jersey to conduct a hybrid type II effectiveness-implementation randomized controlled trial (RCT) evaluating the Mobile-based Obstetric Monitoring for Hypertension and/or Diabetes (MOM-HD) program. The project aims to assess the effectiveness and implementation of the MOM-HD program, which...
- The National Heart Lung and Blood Institute awarded Temple University a Project Grant titled "INTEGRATE RX: INTEGRATING CLINICAL PHARMACISTS IN HIV CARE TO MITIGATE LAST-MILE CHALLENGES AND REDUCE CARDIOVASCULAR DISEASE BURDEN" under CFDA Program 93.837 Cardiovascular Diseases Research. The $589,297 grant, awarded on Aug 25, 2025, will evaluate the clinical effectiveness and cost-effectiveness of a multi-component pharmacist-led implementation strategy to prevent and manage...